Eli Lilly LLY
NYSE LLY
$1,143.30 -6.79 (-0.59%)
At close: Oct 2, 2026 · 4:00 PM EDT

Eli Lilly (LLY) Gains from Sales and Divestitures (2019 - 2024)

Updated

Eli Lilly (LLY) posted Gains from Sales and Divestitures of $180 million for FY2025, down 19.6% from $224 million in FY2024.

Analysis

Eli Lilly (LLY) Gains from Sales and Divestitures (2019 - 2024) Analysis & Trends

Since FY2019, Eli Lilly has reported Gains from Sales and Divestitures for 6 years.

  • Annual Gains from Sales and Divestitures shows a four-year compound annual growth rate of -4.5% (FY2021 to FY2025).
  • The FY2025 figure stands as the lowest annual Gains from Sales and Divestitures since FY2022.
  • Business Quant data shows LLY's Gains from Sales and Divestitures at $224 million in FY2024 (-88.1%), $1.88 billion in FY2023, $156.5 million in FY2022 (-27.5%) and $216 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Vertex Pharmaceuticals 127.87 Bn 99.88 Bn 2.84 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 123.30 Mn
Dec 31, 2023 25.10 Mn
Dec 31, 2022 62.00 Mn
Dec 31, 2019 309.80 Mn
Mar 31, 2019 3.68 Bn
API Access

Eli Lilly Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=LLY&period=max&api_key=YOUR_API_KEY